Cure Alzheimer's FUND
targeting breakthrough research

Q4 2017

Cure Alzheimer's Fund Researchers Take on APOE

Cure Alzheimer's Fund (CureAlz) researchers David Holtzman, M.D., and Guojun Bu, Ph.D., set out to identify the best time to target APOE to limit amyloid accumulation. Of the three most common APOE gene variants, APOE4 is most harmful, because it not only coaxes amyloid to accumulate into plaques, but also competes with it for an efficient exit from the brain. As part of a separate research endeavor involving APOE, David Holtzman's team also showed that it impacts the two other main players in Alzheimer's disease—tau and inflammation.

Given the critical nature of APOE, CureAlz is funding a total of six researchers who have formed a powerful consortium to examine how particular APOE variants influence: 1) tau, 2) inflammation, 3) blood vessel health, 4) microglia, (brain's immune cells) and 5) gene expression in the brain regions most vulnerable to the impact of Alzheimer's disease pathology.

The researchers are:

- **David Holtzman, M.D.** (consortium leader), Washington University, School of Medicine
- **Randall Bateman, M.D.,** Washington University, School of Medicine
- **Guojun Bu, Ph.D.,** Mayo Clinic, Jacksonville
- **Oleg Butovsky, Ph.D.,** Brigham and Women's Hospital, Harvard Medical School
- **Paul Greengard, Ph.D.,** Rockefeller University
- **Cheryl Wellington, Ph.D.,** University of British Columbia

Does APOE have a Time-Limited Effect on Amyloid?

Holtzman and Bu published companion studies in the scientific journal Neuron that examined when APOE has the biggest effect on amyloid. They discovered that during the initial phase of Alzheimer's disease, small amyloid aggregates form in a process called "seeding." Over time, these aggregates experience a period of rapid growth.

The two scientists also were interested in addressing whether APOE had its greatest impact during the initial amyloid seeding phase, later when the plaques are rapidly developing, or throughout disease development. Both labs used mice engineered to produce amyloid, and then increased or decreased the levels of the different variants of the APOE gene. The gene either was selectively activated or blocked at different times in development. They both found that APOE4 had the largest effect on amyloid levels during the seeding process.

continued on page 2 »



Cure Alzheimer's Fund Researchers Take on APOE

continued from page 1 »

The studies also yielded another important finding: APOE4 caused swelling in the nerve connections surrounding the plaques. This occurred both during seeding and during the period of rapid plaque growth. APOE therapies may be effective throughout the disease course as a remedy for preserving neuronal health, even though earlier administration would be necessary to reduce the number of amyloid plaques. Holtzman noted that "administering APOE therapies, after seeding, can still be useful as a way to protect neurons and their connections."

Holztman and Bu agree that we still need to better understand why APOE has the power to aggravate amyloid.

APOE Consortium Researchers

David Holtzman, M.D.

Randall Bateman, M.D.

Guojun Bu, Ph.D.

Oleg Butovsky, Ph.D.

Paul Greengard, Ph.D.

Cheryl Wellington, Ph.D.

APOE therapies may be effective throughout the disease course as a remedy for preserving neuronal health, even though earlier administration would be necessary to reduce the number of amyloid plaques.

Bu explained, "One of the reasons APOE promotes amyloid seeds is because APOE (as well as amyloid) self-aggregates. It tangles up with amyloid, and together they get to the point of no return." He concluded, "We need to find compounds that can reduce aggregation of amyloid, APOE, or both of them together."

APOE's Role in Tangle Formation and Inflammation

Some time after amyloid plaques develop, amyloid triggers the spreading of tau tangles in the brain and an inflammatory process develops. The swollen nerve connections reported in both Holtzman's and Bu's studies hint that APOE4 may be involved in triggering such an inflammatory process. Stronger evidence that APOE plays such a role comes from another set of findings from Holtzman's lab that primarily set out to test APOE's impact on tau.

The results were published in the prestigious scientific journal Nature in September 2017. Mice were genetically engineered to produce a human form of tau that is particularly prone to tangle formation. The mice then were treated with one of three forms of the APOE gene. Those carrying the APOE4 variant showed the greatest quantity of tau tangles and the most shrinkage in brain regions important for memory, compared with mice treated with the other APOE variants or with mice lacking the APOE gene altogether.

In the next phase, Holtzman and Bu tested the impact of APOE on inflammation by combining immune cells extracted from the brain tissue of APOE4 mice with neurons containing human tau in a petri dish. The APOE4 variant unleashed a large immune response that appeared to lead to widespread neuronal damage and death. Holtzman is encouraged by the implications of his results: "Because tau tangles do not appear in substantial numbers until after amyloid plaques are already present, and because they are a good indicator of the amount of brain pathology and cognitive impairment, you can theoretically treat patients with an APOE therapy and still have a big effect after symptoms of Alzheimer's disease symptoms emerge."

Implications for Alzheimer's Disease Treatment

APOE appears to play a role in each of the three pillars of Alzheimer's disease—amyloid, tau and inflammation. Because APOE4 amplified deleterious effects on nerve connection swelling, tau tangle formation and inflammation, and because these three pathologies all follow amyloid deposition, it means that APOE therapies potentially could be administered effectively across a wide timeframe in the disease course and still pack a powerful punch.

Cure Alzheimer's Fund Loses an Exceptional Researcher and a Dear Friend

Ben A. Barres, M.D., Ph.D., lost his battle with pancreatic cancer in late December at the age of 63.

Barres was an acclaimed neuroscientist from Stanford University. His research was groundbreaking in the area of understanding the role of glia cells—those cells that make up the majority of the brain but are *not* nerve cells. In addition to his research, he was a passionate mentor and teacher, and his work had a significant impact on the understanding of the brain and on Alzheimer's disease.

In 2017, Barres became a member of the Cure Alzheimer's Fund Research Consortium. "The intellectual horsepower, innovative turn of mind and humanity Ben brought to some of the world's seemingly intractable medical mysteries had us all in awe," said Tim Armour, CEO of Cure Alzheimer's Fund. "The world has lost an exceptional human being."

Ben A. Barres, M.D., Ph.D.

The Kohnen Family Initiative on Alzheimer's and Related Dementia

Since 2012, the David Kohnen family of Cincinnati has led a fundraising and educational effort on Alzheimer's and related dementia to honor David and other loved ones with this terrible disease.

L to R: Nan Cahall, Jennifer McNair, Tina Kohnen, Dr. Paige de Buys and Suzanne McNabb

From the beginning, David's widow, Tina Kohnen, and daughter, Jennifer McNair, nieces, Suzanne McNabb and Nan Kohnen Cahall, and friend, Dr. Paige de Buys, have researched the best possible way to make a difference in the world of Alzheimer's and related dementia. Because each of them has seen firsthand how devastating this disease is, the Kohnen Family Initiative is committed to doing everything it can to stop Alzheimer's in its tracks. After considerable research, they decided to partner with Cure Alzheimer's Fund.

"We liked their mission and the fact that all money donated goes directly to research with no overhead costs, which is also the way we operate. It has been a good decision for us…and hopefully, for Cure Alzheimer's Fund," Tina Kohnen said. "Our focus has always been twofold—first, to support much-needed research into this dreaded disease, and second, to bring about awareness, helping to spread the word and creating a climate in which people will eventually understand the disease and the behavior of those who suffer from it. I would like to bring the elephant out of the closet and help people become aware of how this disease affects one's personality, particularly in the early stages."

In November, the Kohnen Family Initiative hosted its second State of the Mind reception in Cincinnati. At the event, developmental biologist and CureAlz-funded researcher Andrew S. Yoo, Ph.D., of the Washington University School of Medicine, presented his latest method for studying Alzheimer's using a culture derived from human skin cells similar to Alzheimer's in a Dish. With this tool,

continued on page 4 »

Kohnen Family *continued from page 3 »*

Yoo is able to study neurons of people from across the age spectrum, including those who have Alzheimer's, and learn what cellular properties, intrinsic in aging neurons, make them more susceptible to neurodegenerative disease. Cure Alzheimer's Fund President and CEO Tim Armour and Senior Vice President, Development, John Slattery also presented on the progress of research based on funding made possible from the Kohnen Initiative.

The Initiative has partnered with CureAlz by giving very generously and raising funds within the greater Cincinnati community for Alzheimer's research. To date, the Kohnen Family Initiative has contributed more than $800,000 to funding important projects, including those associated with the Alzheimer's in a Dish discovery and a gamma-secretase modulator (GSM) drug expected to go to trials. The GSM project is being led by Cure Alzheimer's Fund Research Consortium member and neuroscientist Steven Wagner, Ph.D., of the University of California, San Diego School of Medicine.

"Tina and her team are helping us make incredible progress by catalyzing important research with their fundraising and generous gifts," said Tim Armour. "We are very thankful for their years of commitment to our cause and for inspiring others to support the mission."

MOST SUCCESSFUL SYMPOSIUM

On Oct. 19, 2017, we hosted our 7th Annual Symposium at the Boston Public Library featuring Cure Alzheimer's Fund Research Consortium Chair Rudolph Tanzi, Ph.D., and Robert Moir, Ph.D., both of Harvard Medical School/Massachusetts General Hospital. We drew our biggest crowd ever for this event.

The program began with the showing of four award-winning short films as part of the Living With Alzheimer's Film Project, which was followed by a discussion with Lisa Genova, author of "Still Alice," and David Shenk, Senior Adviser to Cure Alzheimer's Fund.



Tanzi then provided an overview of the groundbreaking research Cure Alzheimer's Fund is supporting. We now know that disease pathology begins decades before detectable cognitive symptoms, which means treatment needs to initiate well before this point. "We need early prediction, early detection and early treatment," Tanzi said.

Moir explained how infection in the brain might play a contributory role to the disease. He also shared some promising research, based on his findings, that in addition to the destructive role amyloid has in Alzheimer's, it also may play a protective role in the brain as an anti-microbial peptide.

If you weren't able to join us, watch the recording of it at **curealz.org/symposium**.

Lisa Genova, author of "Still Alice," takes questions from the audience.

Robert Moir, Ph.D.

Cure Alzheimer's Fund founders and board members with Rudy Tanzi, Ph.D. (center).

The Face the Disease ads displayed at the King of Prussia® mall in Pennsylvania.

Face the Disease Campaign in Simon Malls

Last year a representative from mall operator Simon Malls offered to display advertising for Cure Alzheimer's Fund in several of its locations throughout the holiday season.

The ads were designed for the malls' new interactive motion kiosks, and included videos with touch screens to educate people about Alzheimer's disease.

Cathy Ingham of Philadelphia, advocate and supporter of Cure Alzheimer's Fund, was shopping at the King of Prussia® mall with her daughter on Black Friday when she discovered the kiosk featuring CureAlz. "We zeroed in on it and found it to be interactive and informational," Ingham said. "My father had Alzheimer's, and my frustration with the lack of drugs to help him led me to Cure Alzheimer's Fund years earlier. My family and I know this lean and mean organization is not only getting the word out about Alzheimer's, but they are spending their money wisely and moving the ball. They are doing everything right." Cathy's daughter, Lori, who also resides in the Philadelphia area, added, "Until my grandfather was diagnosed with Alzheimer's, I had never heard of the disease. It's so much more common than I knew and so heartbreaking. People of my generation are always looking to make a positive impact, and Cure Alzheimer's Fund is a great place to put your money."

Rudy Tanzi, Ph.D., and Dan Gasby

First Public Service Announcement

This year, Cure Alzheimer's Fund launched its first public service announcement. Designed to educate the public about the disease, the 60-second television spot features Dr. Rudy Tanzi and businessman Dan Gasby talking about Alzheimer's and its impact on those with the disease and their families. The PSA is being shown on TV and also on social media sites, including Facebook and YouTube.

View the spot at **vimeo.com/curealz**.

Stephen Wong, Ph.D.

Wong Presents in Houston

On Dec. 7, Cure Alzheimer's Fund hosted a group of donors from the Houston area at a State of the Mind presentation featuring Research Consortium member Stephen Wong, Ph.D., and John Slattery, Senior Vice President, Development.

Wong's team led the group on a tour of the Houston Methodist Research Institute lab and showed them the Methodist Institute for Technology, Innovation & Education, an innovative virtual hospital and hands-on clinical training facility for health care professionals. The tour was followed by a luncheon at which Wong shared details on the exciting research he is doing evaluating FDA-approved compounds and other drugs as possible therapies for Alzheimer's disease.

He has conducted screenings and investigation on more than 25,000 compounds, including screening 3,500 drug compounds in stem cell-derived neuronal cell cultures (Alzheimer's in a Dish), a scientific tool created with funding from CureAlz.

The studies resulted in the identification of drugs that block tau tangle formation in Alzheimer's in a Dish, which Wong, Rudy Tanzi, Ph.D., of Harvard University/ Massachusetts General Hospital, and others are investigating for potential clinical trials.

State of the Mind presentations are designed to help our donors appreciate how their generosity is fueling the fight against Alzheimer's, increasing the scientific community's understanding of the disease and moving us closer to an effective therapy.

Welcome Lisa

In January, Lisa Bida joined our team as Marketing Manager. Lisa brings more than 20 years of marketing experience to CureAlz, having worked for New Balance and most recently Wellesley College. "Throughout my career, I've developed and sold a lot of *stuff*—sneakers, giftware, toys. As I started to volunteer with organizations like The Wellesley Education Foundation and Wellesley Hills Junior Women's Club, I found great enjoyment and satisfaction from working for causes," she said. "I'm excited to be joining the team and helping to tell CureAlz's story to an even wider audience."

New Alzheimer's Stamp

On Nov. 30, 2017, the U.S. Postal Service® officially issued a new Alzheimer's stamp that will help raise funds to fight the disease. This First-Class™ semipostal stamp, also known as a charity stamp, is sold at a premium rate—65 cents vs. the standard 49 cents—in order to raise money for research. The image of a supportive hand on an aging woman's shoulder with a glimmer of sunlight in the background suggests hope for the future. This stamp is another important step toward raising awareness of the disease among the general public. Purchase it at the post office or online at **store.usps.com**.

100 percent of every donation goes directly to research.

Help us fund research with the highest probability of preventing, slowing or reversing Alzheimer's disease. Donations can be made through our websites, CureAlz.org/donate or WomenAndAlzheimers.org, or sent directly to our office.

For gifts of securities or direct wire transfers, please contact Tim Armour at 877-CURE-ALZ (287-3259) for further information.

Financial Update

	This Quarter	YTD	Inception to Date
Fundraising	$10.7M	$18.5M	$94.2M
Expenses paid for by the board	$0.8M	$3.2M	$18.3M
Research spending	$9.5M	$15.7M	$67.0M

Numbers shown are preliminary for the period and are rounded to the nearest $100,000.

Research Update (Grants approved for funding during the fourth quarter of 2017)

Project/Researcher	Distribution Amount
Gene Expression Throughout Development of Pathology in APPKI Mice; Effects of Human Tau and Aging – John Hardy, Ph.D., and Frances Edwards, Ph.D., University College, London	$198,987
Alzheimer's Genome Project™ – Rudolph Tanzi, Ph.D., Massachusetts General Hospital	$1,500,000
3DDS: Evaluation of Blood-Brain Barrier (BBB) Penetration of Alzheimer's Drug Targets, and Identification of BBB Integrity Enhancers – Se Hoon Choi, Ph.D., and Roger Kamm, Ph.D., Massachusetts General Hospital/Massachusetts Institute of Technology	$200,000
3DDS: Compounds Modulating Microglial Uptake of Amyloid Beta and CD33-Targeted Immunotherapy for Alzheimer's Disease – Ana Griciuc, Ph.D., and Rudolph Tanzi, Ph.D., Massachusetts General Hospital	$250,000
3DDS: High-Throughput Drug Screening for Alzheimer's Disease Using 3-D Human Neural Culture Systems – Doo Yeon Kim, Ph.D., Massachusetts General Hospital	$250,000
3DDS: Uncovering the Molecular Mechanism of Selected Drug Candidates Derived from Systemic Alzheimer's Drug Repositioning – Stephen T. Wong, Ph.D., Houston Methodist Research Institute	$150,000
3DDS: Alzheimer's Disease Stem Cell Drug Screening in 3-D – Weiming Xia, Ph.D., Boston University	$100,000
Therapeutic Modulation of TREM2 Activity – Christian Haass, Ph.D., DZNE Munich	$112,000
SORLA Attenuates Amyloid Beta Toxicity Through Interactions with EphA4 – Huaxi Xu, Ph.D., Sanford Burnham Prebys Medical Discovery Institute	$150,000
Discovery of CK1 Activators for Inducing the Autophagic Degradation of Amyloid Precursor Protein (APP) Beta-CTF – Paul Greengard, Ph.D., Rockefeller University	$450,000
Investigating the Mechanism of APOE4-associated Neuronal Hyperactivity in the Entorhinal Cortex and its Effect on Tauopathy Propagation – Karen Duff, Ph.D., and Tal Nuriel, Ph.D., Columbia University	$200,000
Functional Characterization of GGA3 Mutations Associated With Alzheimer's Disease – Giuseppina Tesco, M.D., Ph.D., Tufts University	$150,000
Genes to Therapies™ (G2T) Centralized Research Core – Wilma Wasco, Ph.D., Massachusetts General Hospital	$200,000
Protein Kinase C in Alzheimer's Disease – Alexandra Newton, Ph.D., University of California, San Diego	$250,000
Interactions Among TREM2, APOE and Sex – Caleb Finch, Ph.D., and Christian Pike, Ph.D., University of Southern California	$156,005
Molecular and Cellular Mechanisms of ACE1 Variant in Alzheimer's Disease – Robert Vassar, Ph.D., Northwestern University	$250,000
A Microfluidics-Based Human Brain Cell 3-D Culture System in Alzheimer's Disease – Hansang Cho, Ph.D., University of North Carolina at Charlotte	$152,350
TREM2: Role in Modulating Amyloid Beta and Tau-Related Pathologies and Neurodegeneration – Marco Colonna, M.D., and David M. Holtzman, M.D., Washington University School of Medicine	$300,000

Exploring Sex Differences in AD Pathogenesis Using 3-D Human Non-Cell-Autonomous Models – Doo Yeon Kim, Ph.D., and Daniel Irimia, M.D., Ph.D., Massachusetts General Hospital	$200,000
Amyloid Beta Kinetics and Enhancing the Diagnostic and Prognostic Cerebrospinal Fluid Biomarkers of Alzheimer's Disease – Randall J. Bateman, M.D., and Norelle C. Wildburger, Ph.D., Washington University School of Medicine	$50,000
Stable Isotope Labeling and Quantitative Mass Spectrometry Imaging of Alzheimer's Disease Pathology in Human Brain – Randall J. Bateman, M.D., and Norelle C. Wildburger, Ph.D, Washington University School of Medicine	$150,000
Impact of Inflammasome Deactivation on Alzheimer's Disease – Vishwa Deep Dixit, D.V.M., Ph.D., Yale School of Medicine	$150,000
Synapse Pruning by Astrocytes: A Potential New Target for Treating Alzheimer's Disease – Won-Suk Chung, Ph.D., KAIST	$150,000
Systemic Inflammatory Networks in Alzheimer's Disease – Filip Swirski, Ph.D., and Matthias Nahrendorf, M.D., Ph.D., Massachusetts General Hospital	$150,000
The Role of the Contact System in Alzheimer's Disease – Sidney Strickland, Ph.D., and Erin H. Norris, Ph.D., The Rockefeller University	$150,000
Targeting Reactive Astrocytes for Therapeutic Intervention in Alzheimer's Disease – Gilbert Gallardo, Ph.D., Washington University School of Medicine	$150,000
Chronic Viral Neuroinfection Mediates Amyloid Beta Deposition in Transgenic Alzheimer's Disease Mice – Robert Moir, Ph.D., Massachusetts General Hospital	$350,000
Regulation of Microglial Lysosome Acidification – Frederick R. Maxfield, Ph.D., Weill Cornell Medical College	$150,000
VGF, a Novel Therapeutic Effector of Alzheimer's Disease Pathogenesis and Progression – Michelle E. Ehrlich, M.D., and Stephen R. Salton, M.D., Ph.D., Icahn School of Medicine at Mount Sinai	$150,000
Gut Microbiome-Mediated Shifts in Amyloid Beta Deposition in a Humanized Alzheimer's Disease Mouse Model – Deepak Vijaya Kumar, Ph.D., Massachusetts General Hospital	$250,000
Mechanisms By Which the Gut Microbiome Influences Amyloid Deposition and Neuroinflammation in the APPswe/PS1DE9 Mouse Model of Amyloid Beta Amyloidosis – Sangram S. Sisodia, Ph.D., University of Chicago	$175,000
Cerebrovascular Dysfunction in AD: Targeting the Mechanisms of Vascular Activation – Paula Grammas, Ph.D., University of Rhode Island	$150,000
Stimulating Proteasome Activity for the Treatment of Alzheimer's Disease – Hermann Steller, Ph.D., The Rockefeller University	$150,000
Targeting Cell Cycle Re-entry Using 3-D Neuron Cultures – George S. Bloom, Ph.D., John S. Lazo, Ph.D., and Elizabeth R. Sharlow, Ph.D., University of Virginia	$190,681
Biochemical Mapping of the GSM Binding Site of Novel Pyridazine-Derived Small Molecule Gamma-Secretase Modulators – Steven L. Wagner, Ph.D., and Yeming Li, Ph.D., University of California, San Diego/Sloan Kettering Institute	$300,000
Novel Chemical Modulators for BACE1-Mediated Cleavage of Amyloid Beta Precursor Protein – Tae-Wan Kim, Ph.D., Columbia University	$150,000
Treating with Gamma-Secretase Modulators to Prevent Neurodegeneration in Mouse Models of Down Syndrome – William C. Mobley, M.D., Ph.D., and Steven L. Wagner, Ph.D., University of California, San Diego	$150,000
Validation of Endogenous Human Antibodies That are Correlated With Avoiding Alzheimer's Disease and Their Corresponding Antigens, for Immunotherapeutic Development – Charles Glabe, Ph.D., University of California, Irvine	$150,000
CIRCUITS: Interpreting Alzheimer's Disease-Associated Genetic Variation at Enhancer Regions – Andreas R. Pfenning, Ph.D., Carnegie Mellon University	$193,786
G2T™ Research Models and Materials – Taconic Biosciences	$334,774
Total	**$9,013,583**

For full abstracts of all funded projects, visit curealz.org/research/funded-research.

Cure Alzheimer's Fund Heroes

Last November, a group of gymnasts, ages 8 to 18, from **Interstate Gymnastics and Dance** in Methuen, Massachusetts, owned by **Dunkan Gould** and **Kevin Gendreau,** raised money for Cure Alzheimer's Fund in order to be able to spend the day with Olympic gymnast **Laurie Hernandez.**

L to R: Dunkan, Laurie and Kevin

"Interstate Gymnastics and Dance was so proud to be able to make memories that will last a lifetime for so many of our students, while raising funds for a great cause that affects so many lives."

—DUNKAN GOULD

Roxana

Roxana Cabral, from Los Angeles, founded **All Heart Cosmetics** in October to help educate and spread awareness for different nonprofit organizations. With vegan and cruelty free products designed for health conscious women, All Heart's ruby red "Remember Me" nail lacquer was released in December to help fight Alzheimer's. One dollar of each bottle sold goes directly to Cure Alzheimer's Fund (while supplies last).

Talbots

Nancy Talbots, founder of the classic women's clothing chain who suffered from Alzheimer's disease, believed in giving back to local communities. Last fall, the Wellesley (Massachusetts) Talbots assistant store manager, **Dorcas Lee,** held a shopping event to uphold Talbots' tradition of giving back—by donating 10 percent of all sales from the event to CureAlz

L to R: Jenny and Jennifer

On Nov. 15, Cure Alzheimer's Fund advocate **Jenny Miller,** president of **Senior Care Concepts,** an elder care community in Providence, Rhode Island, organized a Sip & Shop fundraiser event with **Jennifer Klemmer,** the store manager at **J. McLaughlin** in Providence. Many people came out to shop and the store donated 15 percent of its sales that day to research.

L to R: Jaclyn and Phoebe

The Keynote Sisters—Phoebe, 20, and **Jaclyn Holmes,** 16 of Oakland, Michigan—lost their grandmother, May L. Shuck, M.D., to Alzheimer's two years ago. In her honor, they recorded a CD, "Come What May," and are now selling copies of it at their gigs to raise money for CureAlz, in the hope of coming one step closer to finding a cure.

Jim and Mary

On **Mary Schaus'** birthday last October she didn't ask for elaborate gifts. Instead, she requested that friends and family donate the money they might have spent on her to CureAlz, since Mary's father, Jim Totin, has Alzheimer's. "He's an amazing man of spirit and fun who has had that zapped away. The best gift you can give me is to help find a cure," she said.

The Administration Department at **Wilcox State Prison** in the Georgia Department of Corrections held a holiday bake sale in December to support CureAlz. Staffers made Mississippi mud brownies, key lime cake, cupcakes, hot chocolate on a stick and more homemade goodies to raise money for research.

Residents and guests at the Carriage House.

Last October the **Carriage House,** one of **Northbridge's** senior living communities in Wayland, Massachusetts, held an autumn harvest wine dinner and silent auction for more than 50 residents and their families to raise money for CureAlz.


Bill Gates

Bill Gates Invests in Alzheimer's Research

When billionaire Microsoft founder Bill Gates speaks, people listen.

And when he announced last November he would invest $100 million of his own money in Alzheimer's research, Forbes magazine, Fortune magazine, CNN and other high-profile media outlets jumped on the story. That's a win in and of itself, since Alzheimer's long has been a disease no one has wanted to talk about, much like cancer was years ago.

Forbes spoke with Cure Alzheimer's Fund President and CEO Tim Armour about the announcement. "Funding of research for Alzheimer's disease lags far behind the other top 10 illnesses," Armour said. "Bill Gates and his contributions to research of Alzheimer's disease through private venture funding will not only help elevate awareness of the disease, it will make a true difference."

Gates is investing $50 million in the Dementia Discovery Fund, a private venture fund, and he plans to invest an additional $50 million in start-up efforts over time. "We are optimistic that Gates' sizeable commitment to the eradication of Alzheimer's disease will act as a catalyst for further sizeable investments by others, and we intend to actively encourage that and create the vehicles for doing so," added Armour.

CHARITY NAVIGATOR
★★★★
Four Star Charity

Recognition for Great Work

Cure Alzheimer's Fund was recently recognized by both Good Housekeeping as one of 10 "Best Charities to Give To Right Now" and by Charity Navigator, which awarded CureAlz a four-star designation seven consecutive times and named us one of the three top nonprofits in the country to donate to during Alzheimer's Disease Awareness and Caregivers Month. "Being chosen by these reputable organizations has helped to raise additional awareness for CureAlz and underscores the growing importance of our mission and our unique model of applying all donations to research," said Barbara Chambers, Senior Engagement Officer, Cure Alzheimer's Fund.

Read the Good Housekeeping article at **http://bit.ly/2E1G5tD**.

Cure Alzheimer's FUND

34 Washington St.
Suite 200
Wellesley Hills, MA 02481
p: 877-CURE-ALZ (287-3259)
f: 781-658-2399
e: info@curealz.org
curealz.org

Centre City Tower
650 Smithfield St.
Suite 2015
Pittsburgh, PA 15222
p: 412-261-2785

Mission

Fund research with the highest probability of preventing, slowing or reversing Alzheimer's disease.

Charity Designation

Cure Alzheimer's Fund® is a "doing business as" name for the Alzheimer's Disease Research Foundation, a 501(c)(3) public charity with federal tax ID #52-2396428.

Check out our Facebook page for our most recent posts, photos, videos and more!

Go to **facebook.com/CureAlzheimers**.

Contributing Writer: Patty Bovie
Copy Editor: Colleen O'Neill
Design: Winking Fish